{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T21:48:01Z","timestamp":1768254481571,"version":"3.49.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.intimp.2025.114339","type":"journal-article","created":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T16:33:02Z","timestamp":1740241982000},"page":"114339","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["The safety assessment of ustekinumab on psoriasis and psoriatic arthritis: A real-world analysis based on the FDA adverse event reporting system database"],"prefix":"10.1016","volume":"151","author":[{"given":"Yu","family":"Zheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Jing","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Jun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang-Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Ling","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Yang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui-Lian","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Bu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Er-Xia","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.intimp.2025.114339_bb0005","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases: epidemiology","volume":"76","author":"Takeshita","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2025.114339_bb0010","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/jdv.13854","article-title":"A systematic review of worldwide epidemiology of psoriasis","volume":"31","author":"Michalek","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"3","key":"10.1016\/j.intimp.2025.114339_bb0015","doi-asserted-by":"crossref","DOI":"10.1097\/JD9.0000000000000353","article-title":"Leptin modulates the differentiation of keratinocytes via autophagy in psoriasis patients with metabolic syndrome","volume":"7","author":"Song","year":"2024","journal-title":"Int. J. Dermatol. Venereol"},{"issue":"2","key":"10.1016\/j.intimp.2025.114339_bb0020","first-page":"187","article-title":"Prevalence of psoriasis in children and adolescents in the United States: a claims-based analysis","volume":"17","author":"Paller","year":"2018","journal-title":"J. Drugs Dermatol."},{"issue":"5","key":"10.1016\/j.intimp.2025.114339_bb0025","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1159\/000524199","article-title":"Adverse effects of anti-Interleukin-23 agents employed in patients with psoriasis: a systematic review","volume":"238","author":"Naik","year":"2022","journal-title":"Dermatology"},{"issue":"3","key":"10.1016\/j.intimp.2025.114339_bb0030","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"issue":"10136","key":"10.1016\/j.intimp.2025.114339_bb0035","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","article-title":"The pathogenesis of psoriatic arthritis","volume":"391","author":"Veale","year":"2018","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.intimp.2025.114339_bb0040","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.intimp.2025.114339_bb0045","article-title":"Human NCF1(90H) Variant promotes IL-23\/IL-17-dependent Mannan-induced psoriasis and psoriatic arthritis","volume":"12","author":"Li","year":"2023","journal-title":"Antioxidants (Basel)"},{"issue":"2","key":"10.1016\/j.intimp.2025.114339_bb0050","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19020530","article-title":"Role of the IL-23\/IL-17 Axis in psoriasis and psoriatic arthritis: the clinical importance of its divergence in skin and joints","volume":"19","author":"Boutet","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2025.114339_bb0055","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19010042","article-title":"The origin of skin dendritic cell network and its role in psoriasis","volume":"19","author":"Kim","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.intimp.2025.114339_bb0060","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.4049\/jimmunol.176.3.1908","article-title":"In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin","volume":"176","author":"Piskin","year":"2006","journal-title":"J. Immunol."},{"issue":"10275","key":"10.1016\/j.intimp.2025.114339_bb0065","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.intimp.2025.114339_bb0070","doi-asserted-by":"crossref","first-page":"216","DOI":"10.4161\/mabs.1.3.8593","article-title":"Ustekinumab","volume":"1","author":"Cingoz","year":"2009","journal-title":"MAbs"},{"issue":"8","key":"10.1016\/j.intimp.2025.114339_bb0075","article-title":"FDA approved biologics: can Etanercept and Ustekinumab be considered a first-line systemic therapy for pediatric\/adolescents in moderate to severe psoriasis? A systematic review","volume":"12","author":"Aslam","year":"2020","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.intimp.2025.114339_bb0080","article-title":"Chinese Experts Consensus on Biologic Therapy for Psoriasis#","volume":"3","author":"Chinese Society of Dermatology CDA Dermatology and Venereology Specialized Committee of Chinese Association of Integrative Medicine","year":"2020","journal-title":"Int. J. Dermatol. Venereol."},{"issue":"10273","key":"10.1016\/j.intimp.2025.114339_bb0085","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","article-title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.intimp.2025.114339_bb0090","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/bjd.15750","article-title":"Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial","volume":"178","author":"Langley","year":"2018","journal-title":"Br. J. Dermatol."},{"issue":"8","key":"10.1016\/j.intimp.2025.114339_bb0095","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1093\/ecco-jcc\/jjac030","article-title":"Efficacy and safety of maintenance Ustekinumab for ulcerative colitis through 3 years: UNIFI long-term extension","volume":"16","author":"Abreu","year":"2022","journal-title":"J. Crohns Colitis"},{"issue":"9625","key":"10.1016\/j.intimp.2025.114339_bb0100","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2025.114339_bb0105","doi-asserted-by":"crossref","first-page":"2546161","DOI":"10.1155\/2019\/2546161","volume":"2019","author":"Bai","year":"2019","journal-title":"J Immunol Res"},{"issue":"9","key":"10.1016\/j.intimp.2025.114339_bb0110","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1080\/14712598.2018.1504919","article-title":"Ustekinumab in psoriatic arthritis: need for studies from real-world evidence","volume":"18","author":"Queiro","year":"2018","journal-title":"Expert. Opin. Biol. Ther."},{"issue":"7","key":"10.1016\/j.intimp.2025.114339_bb0115","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1080\/14712598.2018.1492545","article-title":"Ustekinumab for the treatment of psoriasis and psoriatic arthritis: a drug evaluation and literature review","volume":"18","author":"Thibodaux","year":"2018","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.intimp.2025.114339_bb0120","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3389\/fphar.2019.00872","article-title":"Mini review: new treatments in psoriatic arthritis. Focus on the IL-23\/17 Axis","volume":"10","author":"Sakkas","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.intimp.2025.114339_bb0125","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/ard-2022-222879","article-title":"Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study","volume":"82","author":"Gossec","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2025.114339_bb0130","unstructured":"FDA Adverse Event Reporting System Database, Guidance, compliance, & regulatory information. https:\/\/www.fda.gov\/drugs\/guidance-compliance-regulatory-information,(accessed 3 July 2024)."},{"issue":"8","key":"10.1016\/j.intimp.2025.114339_bb0135","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","article-title":"Using MedDRA: implications for risk management","volume":"27","author":"Brown","year":"2004","journal-title":"Drug Saf."},{"issue":"6","key":"10.1016\/j.intimp.2025.114339_bb0140","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"8","key":"10.1016\/j.intimp.2025.114339_bb0145","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"4","key":"10.1016\/j.intimp.2025.114339_bb0150","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.intimp.2025.114339_bb0155","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2147\/CLEP.S365513","article-title":"A real-world disproportionality analysis of Olaparib: data Mining of the Public Version of FDA adverse event reporting system","volume":"14","author":"Shu","year":"2022","journal-title":"Clin. Epidemiol."},{"key":"10.1016\/j.intimp.2025.114339_bb0160","doi-asserted-by":"crossref","first-page":"1322054","DOI":"10.3389\/fimmu.2024.1322054","article-title":"Research progress of Ustekinumab in the treatment of inflammatory bowel disease","volume":"15","author":"Zhang","year":"2024","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2025.114339_bb0165","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1111\/ijd.12802","article-title":"Biologics in dermatology: adverse effects","volume":"54","author":"Sehgal","year":"2015","journal-title":"Int. J. Dermatol."},{"issue":"4","key":"10.1016\/j.intimp.2025.114339_bb0170","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/apt.14852","article-title":"Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn\u2019s disease","volume":"48","author":"Singh","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.intimp.2025.114339_bb0175","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut"},{"issue":"7","key":"10.1016\/j.intimp.2025.114339_bb0180","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1007\/s10620-023-07897-2","article-title":"Ustekinumab versus anti-tumour necrosis factor alpha agents as second-line biologics in Crohn\u2019s disease","volume":"68","author":"Eriksson","year":"2023","journal-title":"Dig. Dis. Sci."},{"issue":"9","key":"10.1016\/j.intimp.2025.114339_bb0185","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/ajg.2012.218","article-title":"Serious infection and mortality in patients with Crohn\u2019s disease: more than 5 years of follow-up in the TREAT\u2122 registry","volume":"107","author":"Lichtenstein","year":"2012","journal-title":"Am. J. Gastroenterol."},{"issue":"12","key":"10.1016\/j.intimp.2025.114339_bb0190","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1038\/ajg.2016.433","article-title":"Crohn\u2019s disease activity and concomitant Immunosuppressants affect the risk of serious and opportunistic infections in patients treated with adalimumab","volume":"111","author":"Osterman","year":"2016","journal-title":"Am. J. Gastroenterol."},{"issue":"5","key":"10.1016\/j.intimp.2025.114339_bb0195","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jdcr.2017.06.015","article-title":"Ustekinumab-induced remission of recalcitrant guttate psoriasis: a case series","volume":"3","author":"Brummer","year":"2017","journal-title":"JAAD Case Rep."},{"issue":"4","key":"10.1016\/j.intimp.2025.114339_bb0200","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/bjd.16083","article-title":"HLA-Cw6 and psoriasis","volume":"178","author":"Chen","year":"2018","journal-title":"Br. J. Dermatol."},{"issue":"3","key":"10.1016\/j.intimp.2025.114339_bb0205","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.det.2014.03.007","article-title":"Chronic actinic dermatitis","volume":"32","author":"Paek","year":"2014","journal-title":"Dermatol. Clin."},{"issue":"2","key":"10.1016\/j.intimp.2025.114339_bb0210","first-page":"160","article-title":"Ustekinumab: a review in the treatment of plaque psoriasis and psoriatic arthritis","volume":"11","author":"Zaghi","year":"2012","journal-title":"J. Drugs Dermatol."},{"issue":"16","key":"10.1016\/j.intimp.2025.114339_bb0215","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1158\/0008-5472.CAN-12-1337","article-title":"Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state","volume":"72","author":"Teng","year":"2012","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2025.114339_bb0220","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/ncb717","article-title":"Interleukin-12 suppresses ultraviolet radiation-induced apoptosis by inducing DNA repair","volume":"4","author":"Schwarz","year":"2002","journal-title":"Nat. Cell Biol."},{"issue":"1","key":"10.1016\/j.intimp.2025.114339_bb0225","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1046\/j.1365-2567.2000.00084.x","article-title":"Reversal of ultraviolet radiation-induced immune suppression by recombinant interleukin-12: suppression of cytokine production","volume":"101","author":"Schmitt","year":"2000","journal-title":"Immunology"},{"issue":"4","key":"10.1016\/j.intimp.2025.114339_bb0230","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/mi.2013.101","article-title":"Interleukin-23 is sufficient to induce rapid de novo gut tumorigenesis, independent of carcinogens, through activation of innate lymphoid cells","volume":"7","author":"Chan","year":"2014","journal-title":"Mucosal Immunol."},{"issue":"18","key":"10.1016\/j.intimp.2025.114339_bb0235","doi-asserted-by":"crossref","first-page":"8328","DOI":"10.1073\/pnas.1003251107","article-title":"IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis","volume":"107","author":"Teng","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.intimp.2025.114339_bb0240","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15042","article-title":"Long-term efficacy and safety of ustekinumab for moderate-to-severe psoriasis: a 9-year real-life experience from a tertiary referral center in Turkey","volume":"34","author":"Babuna Kobaner","year":"2021","journal-title":"Dermatol. Ther."},{"issue":"5","key":"10.1016\/j.intimp.2025.114339_bb0245","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1517\/14740338.2013.808330","article-title":"Long-term safety of ustekinumab for psoriasis","volume":"12","author":"Kumar","year":"2013","journal-title":"Expert Opin. Drug Saf."},{"issue":"6","key":"10.1016\/j.intimp.2025.114339_bb0250","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1080\/14740338.2017.1323864","article-title":"The safety of ustekinumab for the treatment of psoriatic arthritis","volume":"16","author":"L\u00f3pez-Ferrer","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"issue":"4","key":"10.1016\/j.intimp.2025.114339_bb0255","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bjd.12214","article-title":"Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up","volume":"168","author":"Papp","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.intimp.2025.114339_bb0260","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.660203","article-title":"Cutaneous Neuroimmune interactions in peripheral neuropathic pain states","volume":"12","author":"Lowy","year":"2021","journal-title":"Front. Immunol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925003297?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925003297?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T14:44:23Z","timestamp":1741272263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925003297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":52,"alternative-id":["S1567576925003297"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.114339","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The safety assessment of ustekinumab on psoriasis and psoriatic arthritis: A real-world analysis based on the FDA adverse event reporting system database","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.114339","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114339"}}